Results 91 to 100 of about 6,666,035 (292)

Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study

Drug Design, Development and Therapy
Wenwei Yang,1,* Jing Zhang,1,* Guifu Wu,2,* Wen Zhang,1 Aiping Zhou,1 Lin Yang,1 Yongkun Sun1 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of
Yang W, Zhang J, Wu G, Zhang W, Zhou A, Yang L, Sun Y   +6 more
doaj  

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Medical oncology [PDF]

European Journal of Cancer, 2001
openaire   +4 more sources

Immune Microenvironment of Hair Follicles in Tumor Immunotherapy

ImmunoTargets and Therapy
Bo Li,1,* Sitong Jiang,2,* Fan Yang,3 Min Tang,2 Haozhen Lv,1 Lin Li,2 Jianmin Chang1 1Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences ...
Li B, Jiang S, Yang F, Tang M, Lv H, Li L, Chang J   +6 more
doaj  

Supplementum 274: Abstracts of the Swiss Oncology & Hematology Congress (SOHC)

Swiss Medical Weekly, 2023
Swiss Society of Medical Oncology, Swiss Society of Hematology, Swiss Group for Clinical Cancer Research   +2 more
doaj   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Cost-Effectiveness Analysis of Ivonescimab Plus Chemotherapy versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer in China Based on the HARMONi-6 Trial

Risk Management and Healthcare Policy
Feng Xuan,1 Minguang Huang,1 Yan Yang,2 Haoze Bian31Department of Radiation Oncology, Zhuji Affiliated Hospital of Wenzhou Medical University, Shaoxing, People’s Republic of China; 2Department of Medical Oncology, Zhuji Affiliated Hospital of Wenzhou ...
Xuan F, Huang M, Yang Y, Bian H
doaj  

Does transdermal fentanyl work in patients with low BMI? Patient‐reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl

Cancer Medicine, 2019
Background Low body mass index (BMI) is suspected of being associated with low transdermal fentanyl (TDF) blood levels and worse pain relief. Clinical pain data to support this claim are lacking.
Natalie Moryl, Ali Bokhari, Yvona Griffo, Rachel Hadler, Lauren Koranteng, Alexandra Filkins, Tianyu Zheng, Susan D. Horn, Charles E. Inturrisi   +8 more
doaj   +1 more source

The Future of Oncology in Psychiatric Medications

Journal of Clinical Medicine
Recent years have provided numerous reports on the mechanisms of action of psychiatric medications (antidepressants, antipsychotics, mood stabilizers, and antidementia drugs) that directly inhibit the growth of cancer cells, as well as on their indirect effects on the psyche and immune system, and their supportive effects on chemotherapeutic agents ...
openaire   +4 more sources

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source